AllianceBernstein’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.79M Buy
73,349
+17,412
+31% +$836K ﹤0.01% 1701
2026
Q1
$2.78M Buy
55,937
+1,845
+3% +$94K ﹤0.01% 1821
2025
Q4
$2.69M Buy
54,092
+30
+0.1% +$1.46K ﹤0.01% 1841
2025
Q3
$2.58M Buy
54,062
+600
+1% +$24.2K ﹤0.01% 1865
2025
Q2
$1.69M Sell
53,462
-609
-1% -$19.5K ﹤0.01% 2030
2025
Q1
$1.77M Sell
54,071
-91
-0.2% -$3.23K ﹤0.01% 1973
2024
Q4
$1.96M Buy
54,162
+152
+0.3% +$5.35K ﹤0.01% 1967
2024
Q3
$1.68M Sell
54,010
-3,100
-5% -$96.8K ﹤0.01% 2054
2024
Q2
$1.53M Hold
57,110
﹤0.01% 2094
2024
Q1
$1.95M Sell
57,110
-2,790
-5% -$83.1K ﹤0.01% 1938
2023
Q4
$1.73M Sell
59,900
-2,918
-5% -$77.4K ﹤0.01% 2016
2023
Q3
$1.73M Hold
62,818
﹤0.01% 1963
2023
Q2
$1.89M Sell
62,818
-8
-0% -$280 ﹤0.01% 1929
2023
Q1
$2.28M Sell
62,826
-7,970
-11% -$306K ﹤0.01% 1792
2022
Q4
$2.53M Sell
70,796
-2,470
-3% -$85.8K ﹤0.01% 1782
2022
Q3
$2.48M Buy
73,266
+4,161
+6% +$135K ﹤0.01% 1746
2022
Q2
$2M Sell
69,105
-3,794
-5% -$109K ﹤0.01% 1956
2022
Q1
$2.36M Buy
72,899
+176
+0.2% +$5.4K ﹤0.01% 1988
2021
Q4
$2.12M Buy
72,723
+93
+0.1% +$2.82K ﹤0.01% 2111
2021
Q3
$1.94M Sell
72,630
-6,850
-9% -$184K ﹤0.01% 2189
2021
Q2
$2.45M Buy
79,480
+5,424
+7% +$166K ﹤0.01% 2067
2021
Q1
$1.94M Sell
74,056
-23,880
-24% -$668K ﹤0.01% 2122
2020
Q4
$2.46M Buy
97,936
+24,996
+34% +$538K ﹤0.01% 1857
2020
Q3
$1.52M Sell
72,940
-1,410
-2% -$32K ﹤0.01% 1989
2020
Q2
$1.77M Buy
74,350
+2,160
+3% +$47.7K ﹤0.01% 1911
2020
Q1
$1.3M Buy
72,190
+100
+0.1% +$2.1K ﹤0.01% 1913
2019
Q4
$1.71M Sell
72,090
-64,870
-47% -$1.58M ﹤0.01% 2048
2019
Q3
$3.76M Sell
136,960
-11,900
-8% -$353K ﹤0.01% 1567
2019
Q2
$4.93M Buy
148,860
+21,300
+17% +$730K ﹤0.01% 1425
2019
Q1
$4.47M Hold
127,560
﹤0.01% 1444
2018
Q4
$4.24M Sell
127,560
-400
-0.3% -$17.2K ﹤0.01% 1379
2018
Q3
$6.44M Hold
127,960
﹤0.01% 1150
2018
Q2
$7.66M Buy
127,960
+20,520
+19% +$1.06M 0.01% 1068
2018
Q1
$4.92M Sell
107,440
-5,770
-5% -$241K ﹤0.01% 1226
2017
Q4
$4.51M Hold
113,210
﹤0.01% 1278
2017
Q3
$4.53M Sell
113,210
-19,530
-15% -$845K ﹤0.01% 1268
2017
Q2
$5.72M Sell
132,740
-17,870
-12% -$636K ﹤0.01% 1148
2017
Q1
$4.71M Sell
150,610
-87,600
-37% -$2.35M ﹤0.01% 1225
2016
Q4
$6.01M Buy
238,210
+17,780
+8% +$397K 0.01% 1092
2016
Q3
$5.45M Buy
220,430
+91,360
+71% +$2.07M ﹤0.01% 1084
2016
Q2
$2.63M Buy
129,070
+57,200
+80% +$1.01M ﹤0.01% 1482
2016
Q1
$1.1M Buy
71,870
+15,730
+28% +$205K ﹤0.01% 2038
2015
Q4
$755K Sell
56,140
-6,100
-10% -$94.4K ﹤0.01% 2271
2015
Q3
$873K Buy
62,240
+1,540
+3% +$28.6K ﹤0.01% 2236
2015
Q2
$1.03M Sell
60,700
-72,570
-54% -$1.03M ﹤0.01% 2261
2015
Q1
$1.61M Buy
133,270
+129,070
+3,073% +$1.22M ﹤0.01% 1889
2014
Q4
$35K Sell
4,200
-4,200
-50% -$35.3K ﹤0.01% 3153
2014
Q3
$73K Hold
8,400
﹤0.01% 3025
2014
Q2
$92K Buy
8,400
+7,692
+1,086% +$68.5K ﹤0.01% 3012
2014
Q1
$6K Sell
708
-4,600
-87% -$42.4K ﹤0.01% 3328
2013
Q4
$40K Sell
5,308
-6,800
-56% -$47.5K ﹤0.01% 3019
2013
Q3
$89K Sell
12,108
-3,418
-22% -$23K ﹤0.01% 2992
2013
Q2
$100K Buy
+15,526
New +$91.4K ﹤0.01% 2949

Other funds holding SUPN

AllianceBernstein's SUPN Position: Q2 2026 in Review

AllianceBernstein increased its Supernus Pharmaceuticals (SUPN) stake by 31% in Q2 2026, buying an estimated $836K and bringing the position to 73,349 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

AllianceBernstein first reported a position in SUPN in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.66M in Q2 2018. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • AllianceBernstein held 73,349 shares of Supernus Pharmaceuticals worth $3.79M as of Q2 2026.
  • AllianceBernstein bought 17,412 Supernus Pharmaceuticals shares in Q2 2026, an estimated $836K.
  • Supernus Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1701 holding.
  • AllianceBernstein first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • AllianceBernstein's Supernus Pharmaceuticals position peaked at $7.66M in Q2 2018.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.